399 related articles for article (PubMed ID: 29741286)
21. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
23. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
26. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues.
Jang TY; Wei YJ; Liu TW; Yeh ML; Liu SF; Hsu CT; Hsu PY; Lin YH; Liang PC; Hsieh MH; Ko YM; Tsai YS; Chen KY; Lin CC; Tsai PC; Wang SC; Huang CI; Lin ZY; Chen SC; Chuang WL; Huang JF; Dai CY; Huang CF; Yu ML
Sci Rep; 2021 Apr; 11(1):8184. PubMed ID: 33854160
[TBL] [Abstract][Full Text] [Related]
27. Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis.
Su TH; Peng CY; Tseng TC; Yang HC; Liu CJ; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Feb; 221(4):589-597. PubMed ID: 31574141
[TBL] [Abstract][Full Text] [Related]
28. Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis.
Techathuvanan K; Srisajjakul S; Pongpaibul A; Limsrichamrern S; Charatcharoenwitthaya P; Chainuvati S; Tanwandee T; Chotiyaputta W
J Med Assoc Thai; 2015 Apr; 98(4):334-42. PubMed ID: 25958707
[TBL] [Abstract][Full Text] [Related]
29. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract][Full Text] [Related]
30. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.
Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ
Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062
[TBL] [Abstract][Full Text] [Related]
31. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
32. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
[TBL] [Abstract][Full Text] [Related]
33. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
34. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
35. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B.
Hsu YC; Jun T; Huang YT; Yeh ML; Lee CL; Ogawa S; Cho SH; Lin JT; Yu ML; Nguyen MH; Tanaka Y
Aliment Pharmacol Ther; 2018 Nov; 48(10):1128-1137. PubMed ID: 30306612
[TBL] [Abstract][Full Text] [Related]
36. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
[TBL] [Abstract][Full Text] [Related]
37. Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Zhang Y; Wang C; Li H; Ding Y
Medicine (Baltimore); 2019 Jan; 98(3):e13929. PubMed ID: 30653099
[TBL] [Abstract][Full Text] [Related]
38. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
[TBL] [Abstract][Full Text] [Related]
39. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
[TBL] [Abstract][Full Text] [Related]
40. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
